CG Oncology Q3 2026: EPS Beat and a Phase 3 Catalyst Due This Month

CG Oncology posted a Q3 2026 GAAP loss of $0.64 per share, beating expectations. Revenue cleared the analyst forecast, though the absolute top line dipped from a year earlier and cost of sales exceeded revenue entirely, a reminder that the company remains in clinical-stage territory.

The net loss widened to $56.89 million from the prior-year quarter, driven largely by R&D spending that climbed on higher clinical trial costs, manufacturing scale-up work, and increased headcount. G&A expenses edged down, a modest offset.

The catalyst schedule drives the stock in the near term. PIVOT-006 Phase 3 topline data for cretostimogene in intermediate-risk and high-grade Ta non-muscle-invasive bladder cancer is expected this month, and CEO Arthur Kuan described it as the first randomized registrational trial in that population. December is set to bring 12-month data from both the CORE-008 Cohort CX and BOND-003 Cohort P studies, adding further evidence across the broader NMIBC landscape.

Alongside the data readouts, CG Oncology expects to complete a Biologics License Application submission for BCG-unresponsive NMIBC before the end of Q4 2026. Cretostimogene already holds FDA Fast Track and Breakthrough Therapy designations for that indication, and the clinical program spans more than 700 patients. The company appointed Isabel Kalofonos as Chief Commercial Officer in October 2026, signaling it is building toward a launch.

With $984.46 million in cash, cash equivalents, and marketable securities, management said it expects to fund operations through 2029, providing a runway that covers multiple regulatory milestones without an immediate need to raise capital. The EPS history shows losses have been widening through most of 2026, while the balance sheet scale relative to the near-term catalyst density has defined the investment thesis here.